Sex Differences in the Neural Mechanisms Mediating Addiction: a New Synthesis and Hypothesis Jill B Becker1,2,3,4*, Adam N Perry1 and Christel Westenbroek1
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Brain Imaging
Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters. -
Specific PET-Ligands for Selected 5-Htand GABA A-Receptor Subtypes
Specific PET-ligands for Selected 5-HT and GABAA-Receptor Subtypes PET-Liganden mit Spezifität für definierte 5-HT und GABAA-Rezeptor-Subtypen Dissertation zur Erlangung des Grades „Doktor der Naturwissenschaften“ am Fachbereich Biologie der Fabian Debus geb. am 19.09.1976 in Frankfurt am Main Mainz, im März 2008 Erklärung Hiermit versichere ich, dass ich die vorliegende Dissertation eigenständig verfasst und keine anderen als die angegebenen Hilfsmittel verwendet habe. Die Dissertation habe ich weder als Arbeit für eine staatliche oder andere wissenschaftliche Prüfung eingereicht noch ist sie oder ein Teil dieser als Dissertation bei einer anderen Fakultät oder einem anderem Fachbereich eingereicht worden. Mainz, im März 2008 II Dekan: 1. Berichterstatter: 2. Berichterstatter: Tag der mündlichen Prüfung: 28.05.2008 III Danksagung Eine solche Schrift kann niemals als Ergebnis der Arbeit eines Einzelnen, sondern sollte immer als Resultat der Arbeit einer großen Anzahl von fleißigen Menschen betrachtet werden, die dabei mitgeholfen haben, dass aus einer Idee ein gelungenes Projekt wurde. Bei meinen beiden Betreuern, Prof. Dr. H. L. und Prof. Dr. F. R., möchte ich mich für das spannende und abwechslungsreiche Thema bedanken. Außerdem für Ihr Vertrauen und Ihre Diskussionsbereitschaft. Insbesondere Herrn Prof. Dr. H. L. möchte ich für seine Unterstützung und seine vorbildliche Betreuung danken. Ich hätte mir keinen besseren Doktorvater wünschen können und bin sehr dankbar für alles, was ich in diesen drei Jahren in seiner Arbeitsgruppe lernen durfte. Besonderer Dank gebührt der gesamten Arbeitsgruppe für Ihre herzliche Gemeinschaft und das produktive Miteinander. Im Einzelnen gebührt Frau R. Dank für das Licht im Dunkel der Bürokratie. Frau B. -
Analysis of Consumption of Energy Drinks by a Group of Adolescent Athletes
International Journal of Environmental Research and Public Health Article Analysis of Consumption of Energy Drinks by a Group of Adolescent Athletes Dariusz Nowak 1,* and Artur Jasionowski 2 1 Department of Nutrition and Dietetics, Faculty of Health Sciences, Nicolaus Copernicus University in Toru´n,Ludwik Rydygier Collegium Medicum in Bydgoszcz, D˛ebowa3, Bydgoszcz 85-626, Poland 2 Department of Theoretical Foundations of Biomedical Sciences and Medical Informatics, Faculty of Pharmacy, Nicolaus Copernicus University in Toru´n, Ludwik Rydygier Collegium Medicum in Bydgoszcz, D˛ebowa3, Bydgoszcz 85-626, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-525-855-401; Fax: +48-525-855-403 Academic Editor: María M. Morales Suárez-Varela Received: 28 April 2016; Accepted: 5 July 2016; Published: 29 July 2016 Abstract: Background: Energy drinks (EDs) have become widely popular among young adults and, even more so, among adolescents. Increasingly, they are consumed by athletes, particularly those who have just begun their sporting career. Uncontrolled and high consumption of EDs, in addition to other sources of caffeine, may pose a threat to the health of young people. Hence, our objective was to analyze the consumption of EDs among teenagers engaged in sports, including quantity consumed, identification of factors influencing consumption, and risks associated with EDs and EDs mixed with alcohol (AmEDs). Methods: The study involved a specially designed questionnaire, which was completed by 707 students, 14.3 years of age on average, attending secondary sports schools. Results: EDs were consumed by 69% of the young athletes, 17% of whom drank EDs quite often: every day or 1–3 times a week. -
The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/ Hyperactivity Disorder
REVIEW The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/ Hyperactivity Disorder Natalia del Campo, Samuel R. Chamberlain, Barbara J. Sahakian, and Trevor W. Robbins Through neuromodulatory influences over fronto-striato-cerebellar circuits, dopamine and noradrenaline play important roles in high-level executive functions often reported to be impaired in attention-deficit/hyperactivity disorder (ADHD). Medications used in the treatment of ADHD (including methylphenidate, dextroamphetamine and atomoxetine) act to increase brain catecholamine levels. However, the precise prefrontal cortical and subcortical mechanisms by which these agents exert their therapeutic effects remain to be fully specified. Herein, we review and discuss the present state of knowledge regarding the roles of dopamine (DA) and noradrenaline in the regulation of cortico- striatal circuits, with a focus on the molecular neuroimaging literature (both in ADHD patients and in healthy subjects). Recent positron emission tomography evidence has highlighted the utility of quantifying DA markers, at baseline or following drug administration, in striatal subregions governed by differential cortical connectivity. This approach opens the possibility of characterizing the neurobiological underpinnings of ADHD (and associated cognitive dysfunction) and its treatment by targeting specific neural circuits. It is anticipated that the application of refined and novel positron emission tomography methodology will help to disentangle the overlapping and dissociable contributions of DA and noradrenaline in the prefrontal cortex, thereby aiding our understanding of ADHD and facilitating new treatments. Key Words: Attention-deficit/hyperactivity disorder, dopamine, DA and NA in the pathophysiology of ADHD, with a focus on the frontostriatal circuits, nigrostriatal projections, noradrenaline, pos- molecular neuroimaging literature. -
Molecular Genetics of Alzheimer's Disease
DkYb[_Y7Y_ZiWdZCeb[YkbWh8_ebe]o 23 I[h_[i;Z_jeh >$@$=heii Institut für Biochemie Biozentrum Am Hubland 97074 Würzburg Germany Dieter B. Wildenauer (Ed.) Molecular Biology of Neuropsychiatric Disorders With 15 Figures and 8 Tables Editor Dieter B. Wildenauer Graylands Hospital Center for Clinical Research in Neuropsychiatry (CCRN) Claremont WA 6910 Australia ISBN 978-3-540-85382-4 e-ISBN 978-3-540-85383-1 ISSN 0933-1891 Library of Congress Control Number: 2008933566 © 2009 Springer-Verlag Berlin Heidelberg This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law. The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Cover design: Boekhorst Design BV, The Netherlands Printed on acid-free paper 9 8 7 6 5 4 3 2 1 springer.com Preface The intention of this book is to give an overview about ongoing research into molecular causes for disorders that affect the human brain. These disorders afflict mainly human behavior and are, since borders between “normal” and “abnormal” behaviors are continuous and hard to define, not always easy to diagnose. -
And D2-Type Dopamine Receptors Are Linked to Motor Response Inhibition in Human Subjects
5990 • The Journal of Neuroscience, April 15, 2015 • 35(15):5990–5997 Behavioral/Cognitive Striatal D1- and D2-type Dopamine Receptors Are Linked to Motor Response Inhibition in Human Subjects Chelsea L. Robertson,1,5 Kenji Ishibashi,3,4 Mark A. Mandelkern,5,6 Amira K. Brown,3 Dara G. Ghahremani,3 Fred Sabb,3 Robert Bilder,3 Tyrone Cannon,2 Jacqueline Borg,2 and Edythe D. London1,3,4,5 Departments of 1Molecular and Medical Pharmacology, and 2Psychology, 3Department of Psychiatry and Biobehavioral Sciences, The Semel Institute for Neuroscience and Human Behavior at UCLA, and 4Brain Research Institute, University of California, Los Angeles, Los Angeles, California 90024, 5Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, California 90073, and 6Department of Physics, University of California, Irvine, Irvine, California 92697 Motor response inhibition is mediated by neural circuits involving dopaminergic transmission; however, the relative contributions of dopaminergic signaling via D1- and D2-type receptors are unclear. Although evidence supports dissociable contributions of D1- and D2-type receptors to response inhibition in rats and associations of D2-type receptors to response inhibition in humans, the relationship between D1-type receptors and response inhibition has not been evaluated in humans. Here, we tested whether individual differences in striatal D1- and D2-type receptors are related to response inhibition in human subjects, possibly in opposing ways. Thirty-one volunteers participated. Response inhibition was indexed by stop-signal reaction time on the stop-signal task and commission errors on the continuous performance task, and tested for association with striatal D1- and D2-type receptor availability [binding potential referred to 11 18 nondisplaceable uptake (BPND )], measured using positron emission tomography with [ C]NNC-112 and [ F]fallypride, respectively. -
Radiochemical Catalog 2020
Your Labeling Company. Radiochemical Catalog 2020 www.rctritec.com Version 2020.2 RC TRITEC AG Speicherstrasse 60a CH-9053 Teufen Tel. +41 71 335 73 73 [email protected] www.rctritec.com Your Labeling Company. RCTT0063: 1,3-Di-o-tolylguandine (DTG) 4 RCTT0675: D/L-2,5-Dimethoxy-4-iodoamphetamine 4 RCTT0701: 4-DAMP 4 RCTT0666: 7-OH-DPAT 4 RCTT0155:AF-DX 384 4 RCTT0330: Atazanavir 4 RCTT0540: Atorvastatin, calcium salt 5 RCTT0532: Batrachotoxinin A, 20-a-benzoate 5 RCTT0470: Clomipramine 5 RCTT0644: Digoxin 5 RCTT0233: Cis-Diltiazem 5 RCTT0033: Dofetilide 5 RCTT0021: Dolutegravir 6 RCTT0796: Dopamine 6 RCTT0748: DPA-714 6 RCTT0424: DPCPX 6 RCTT0051: EMPA 6 RCTT0122: Fallypride 6 RCTT0801: Flumazenil 7 RCTT0777: Glibenclamide 7 RCTT0282: GR 113808 7 RCTT0402: GSK1059865 7 RCTT0688: ICI 118, 551, hydrochloric acid salt 7 RCTT0518: Imipramine, hydrochloric acid salt 7 RCTT0455: Kallidin, (des-Arg10, Leu9) 8 RCTT0581: L-655,708 8 RCTT0340: Lopinavir 8 RCTT0300: Methylspiperone 8 RCTT0324: Muscimol 8 RCTT1001: NaBT4 8 RCTT0650: Naltrindole, hydrochloric acid salt 9 RCTT0430: NECA 9 RCTT0313: Nisoxetine, hydrochloric acid salt 9 RCTT0006: Nitrendipine 9 RCTT0833: NSP ([H-3]N-Succinimidyl propionate) 9 RCTT0633: Ouabain 9 RCTT0345: PBR28 10 RCTT0691: PK 11195 10 RCTT0823: Raclopride 10 RCTT0091: Ritonavir 10 RCTT0202: D/L-Rosiglitazone 10 RCTT0461: SB 674042 10 RCTT0525: SCH 23390 11 RCTT0734: SIL26 11 Important Notice: In order to receive our tritium labeled products you will need a valid license for handling and receiving radioactive material. Please send the license to [email protected] to guarantee a rapid turnaround of your order. 2 Your Labeling Company. -
Roland R. Griffiths CV
June 2020 CURRICULUM VITAE ROLAND R. GRIFFITHS EDUCATION: B.S. Occidental College 1968 Los Angeles, California Psychology (Honors) Ph.D. University of Minnesota 1972 Minneapolis, Minnesota Psychology (Major) Pharmacology (Minor) PUBLICATIONS BY AREAS OF SPECIALIZATION: Psychedelics Caffeine self-administration, withdrawal, subjective effects, and addiction Sedative self-administration and sedative effects Cigarette smoking and nicotine self-administration Alcohol self-administration Baboon drug self-administration and drug discrimination Miscellaneous All Publications ACADEMIC POSITIONS: 2019-present Director, Johns Hopkins Center for Psychedelic and Consciousness Research 1987-present Professor of Behavioral Biology Department of Psychiatry & Behavioral Sciences The Johns Hopkins University School of Medicine Baltimore, Maryland 1987-present Professor of Neuroscience Department of Neuroscience The Johns Hopkins University School of Medicine Baltimore, Maryland 1983-1986 Associate Professor of Neuroscience Department of Neuroscience The Johns Hopkins University School of Medicine 2 Back to Areas of Specialization Baltimore, Maryland 1978-1986 Associate Professor of Behavioral Biology Department of Psychiatry & Behavioral Sciences The Johns Hopkins University School of Medicine Baltimore, Maryland 1972-1978 Assistant Professor of Behavioral Biology Department of Psychiatry & Behavioral Sciences The Johns Hopkins University School of Medicine Baltimore, Maryland POSITIONS HELD: 1975-1984 Research Chief Department of Psychiatry Baltimore City Hospitals Baltimore, Maryland 1972-1975 Research Associate Department of Psychiatry Baltimore City Hospitals Baltimore, Maryland 1969-1972 Consultant in Behavior Modification Faribault State Hospital Faribault, Minnesota 1968-1972 USPHS Pre-doctoral Research Fellow, Psychopharmacology University of Minnesota Minneapolis, Minnesota 3 Back to Areas of Specialization POSTDOCTORAL FELLOWS SUPERVISED: L. DiAnne Bradford, 1976-1978; Jack E. Henningfield, 1978-1980; Nancy A. Ator, 1978-1982; Scott E. -
Sfn2015 Items of Interest
Presentations and Posters of Interest Society for Neuroscience Meeting (2015) 34.01/A100. Estradiol rapidly attenuates ORL-1 receptor-mediated inhibition of proopiomelanocortin neurons via Gq-coupled, membrane-initiated signaling *K. M. CONDE1, C. MEZA2, M. KELLY3, K. SINCHAK4, E. WAGNER2; 1Grad. Col. of Biomed. Sci., 2Col. of Osteo. Med. of the Pacific, Western Univ. of Hlth. Sci., Pomona, CA; 3 Dept. of Physiol. & Pharmacol., Oregon Hlth. and Sci. Univ., Portland, OR; 4California State University, Long Beach, Long Beach, CA Ovarian estrogens act through multiple receptor signaling mechanisms that converge on hypothalamic arcuate nucleus (ARH) proopiomelanocortin (POMC) neurons. A subpopulation of these neurons project to the medial preoptic nucleus (MPN) to regulate lordosis. Orphanin FQ/nociception (OFQ/N) via its opioid-like receptor (ORL-1) regulates lordosis through direct actions on these MPN-projecting POMC neurons. Based o an ever-burgeoning precedence for fast steroid actions, we explored whether estradiol excites ARH POMC neurons by rapidly attenuating inhibitory ORL-1 signaling in these cells. Experiments were carried out in hypothalamic slices prepared from ovariectomized female rats injected one-week prior with the retrograde tracer Fluorogold into the MPN. During electrophysiologic recordings, cells were held at or near -60 mV. Post-hoc identification of neuronal phenotype was determined via immunohistofluorescence. In vehicle-treated slices OFQ/N caused a robust outward current/hyperpolarization via activation of GIRK channels. This OFQ/N-induced outward current was attenuated by 17-β estradiol (E2, 100nM). The 17α enantiomer of E2 had n effect. The OFQ/N-induced response was also attenuated by an equimolar concentration of E2 conjugated to BSA. -
Improved Synthesis of [18F] Fallypride and Characterization of A
Huhtala et al. EJNMMI Radiopharmacy and Chemistry (2019) 4:20 EJNMMI Radiopharmacy https://doi.org/10.1186/s41181-019-0071-6 and Chemistry RESEARCH ARTICLE Open Access Improved synthesis of [18F] fallypride and characterization of a Huntington’s disease mouse model, zQ175DN KI, using longitudinal PET imaging of D2/D3 receptors Tuulia Huhtala1*† , Pekka Poutiainen2,3†, Jussi Rytkönen1, Kimmo Lehtimäki1, Teija Parkkari1, Iiris Kasanen1, Anu J. Airaksinen4, Teija Koivula4, Patrick Sweeney1, Outi Kontkanen1, John Wityak5, Celia Dominiquez5 and Larry C. Park5* * Correspondence: tuulia.huhtala@ crl.com; [email protected] Abstract †Tuulia Huhtala and Pekka Poutiainen contributed equally to Purpose: Dopamine receptors are involved in pathophysiology of neuropsychiatric this work. diseases, including Huntington’s disease (HD). PET imaging of dopamine D2 receptors 1Charles River Discovery Services, (D2R) in HD patients has demonstrated 40% decrease in D2R binding in striatum, and Microkatu 1, 70210 Kuopio, Finland 5CHDI Management/CHDI D2R could be a reliable quantitative target to monitor disease progression. A D2/3R 18 Foundation, Los Angeles, CA, USA antagonist, [ F] fallypride, is a high-affinity radioligand that has been clinically used to Full list of author information is study receptor density and occupancy in neuropsychiatric disorders. Here we report an available at the end of the article improved synthesis method for [18F]fallypride. In addition, high molar activity of the ligand has allowed us to apply PET imaging to characterize D2/D3 receptor density in striatum of the recently developed zQ175DN knock-in (KI) mouse model of HD. Methods: We longitudinally characterized in vivo [18F] fallypride -PET imaging of D2/D3 receptor densities in striatum of 9 and 12 month old wild type (WT) and heterozygous (HET) zQ175DN KI mouse. -
Intravenous and Oral Caffeine Self-Administration in Rats
Drug and Alcohol Dependence 203 (2019) 72–82 Contents lists available at ScienceDirect Drug and Alcohol Dependence journal homepage: www.elsevier.com/locate/drugalcdep Intravenous and oral caffeine self-administration in rats T ⁎ Curtis A. Bradley, Matthew I. Palmatier Department of Psychology, East Tennessee State University, 420 Rogers Stout Hall, P.O. Box 70649, Johnson City, TN, 37614, United States ARTICLE INFO ABSTRACT Keywords: Caffeine is widely consumed for its psychoactive effects worldwide. No pre-clinical study has established reliable Caffeine caffeine self-administration, but we found that caffeine can enhance the reinforcing effects of non-drug rewards. Reinforcement The goal of the present studies was to determine if this effect of caffeine could result in reliable caffeine self- Operant administration. In 2 experiments rats could make an operant response for caffeine delivered in conjunction with Self-administration an oral ‘vehicle’ including saccharin (0.2% w/v) as a primary reinforcer. In Experiment 1, intravenous (IV) Oral caffeine infusions were delivered in conjunction with oral saccharin for meeting the schedule of reinforcement. Intravenous In control conditions, oral saccharin alone or presentations of IV caffeine alone served as the reinforcer. In Experiment 2, access to caffeine was provided in an oral vehicle containing water, decaffeinated instant coffee (0.5% w/v), or decaffeinated coffee and saccharin (0.2%). The concentration of oral caffeine was then ma- nipulated across testing sessions. Oral and IV caffeine robustly increased responding for saccharin in a manner that was repeatable, reliable, and systematically related to unit IV dose. However, the relationship between oral caffeine dose and operant behavior was less systematic; the rats appeared to titrate their caffeine intake by reducing the consummatory response (drinking) rather than the appetitive response (lever pressing). -
Application of Pharmacokientic/Pharmacodynamic Modeling Mura
JPET Fast Forward. Published on July 15, 2013 as DOI: 10.1124/jpet.112.199794 JPETThis Fast article Forward. has not been Published copyedited andon formatted. July 17, The 2013 final asversion DOI:10.1124/jpet.112.199794 may differ from this version. JPET #199794 PiP Translation of Central Nervous System Occupancy from Animal Models: Application of Pharmacokientic/Pharmacodynamic Modeling Murad Melhem Institute for Clinical Pharmacodynamics Downloaded from jpet.aspetjournals.org at ASPET Journals on September 30, 2021 1 Copyright 2013 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on July 15, 2013 as DOI: 10.1124/jpet.112.199794 This article has not been copyedited and formatted. The final version may differ from this version. JPET #199794 PiP Condensed running title: Translational aspects of neuroimaging and target engagement. Correspondence: Murad R. Melhem, PhD. Institute for Clinical Pharmacodynamics, 43 British American Blvd., Latham, NY 12110, USA, Downloaded from Telephone: 1-518-429-2600, Facsimile: 1-518-429-2601, jpet.aspetjournals.org E-mail: [email protected] Number of text pages: 12 (including abstract) Number of tables: 0 at ASPET Journals on September 30, 2021 Number of figures: 0 Number of references: 59 Number of words in the abstract: 201 Number of words in the introduction: 559 Number of words in the rest of manuscript: 2103 Section assignment: Neuropharmacology 2 JPET Fast Forward. Published on July 15, 2013 as DOI: 10.1124/jpet.112.199794 This article has not been